Objectives: Genetic determinants conferring resistance to macrolide, lincosamide, and streptogramin B (MLSB) via ribosomal modification such as, erm, msrA/B and ereA/B genes are distributed in bacteria. The main goals of this work were to evaluate the dissemination of MLSB resistance phenotypes and genotypes in methicillin-resistant Staphylococcus aureus (MRSA) isolates collected from clinical samples. Methods: A total of 106 MRSA isolates were studied. Isolates were recovered from 3 hospitals in Tehran between May 2016 to July 2017. The prevalence of MLSB-resistant strains were determined by D-test, and then M-PCR was performed to identify genes encoding resistance to macrolides, lincosamides, and streptogramins in the tested isolates. Results: The frequency of constitutive resistance MLSB, inducible resistance MLSB and MSB resistance were 56.2%, 22.9%, and 16.6%, respectively. Of 11 isolates with the inducible resistance MLSB phenotype, ermC, ermB, ermA and ereA were positive in 81.8%, 63.6%, 54.5% and 18.2% of these isolates, respectively. In isolates with the constitutive resistance MLSB phenotype, the prevalence of ermA, ermB, ermC, msrA, msrB, ereA and ereB were 25.9%, 18.5%, 44.4%, 0.0%, 0.0%, 11.1% and 0.0%, respectively. Conclusion: Clindamycin is commonly administered in severe MRSA infections depending upon the antimicrobial susceptibility findings. This study showed that the D-test should be used as an obligatory method in routine disk diffusion assay to detect inducible clindamycin resistance in MRSA so that effective antibiotic treatment can be provided.
Introduction
Staphylococcus aureus causes a broad variety of illnesses in human beings from minor skin soft-tissue infections to intense infections such as septicemia, toxic shock syndrome, endocarditis and severe pneumonia [1] . At the beginning of 1961, the increasing rate of methicillin-resistant S. aureus (MRSA), and its distribution in therapeutic centers and the community appeared a noteworthy problem worldwide [2] . There are many drugs appropriate for the treatment of Staphylococcal infection such as aminoglycosides, tetracyclines, fluoroquinolones, macrolide (erythromycin), lincosamide *Corresponding author: Ramazan Rajabnia (clindamycin), and vancomycin, linezolid, and daptomycin, but they swiftly lose their healing potential because of the capacity of bacteria to progress towards effective mechanisms to challenge these antimicrobials [3] . Use of a macrolide, lincosamide and streptogramin B (MLSB) provides a narrow therapeutic range for treating Staphylococcal infections, but they are often considered as a substitute therapeutic regimen [4] . There are 3 different mechanisms of resistance to MLSB including: (1) the msr gene which encodes active efflux pump; (2) the lun gene which encodes drug inactivation; and (3) ribosomal binding site alteration (by methylation and/or mutation within the 23s rRNA gene), encoded by erm cluster/ genes (ermA, ermB, ermC, and ermF) among which, ermA and ermC are the main genes corresponding for resistance to MLSB in Staphylococci, which can be constitutive or inducible.
The ermA gene is situated on transposon Tn 554, which has insertion sites on the S. aureus chromosome [4] [5] [6] . The ermB gene is carried by transposon Tn551. The ermC gene has been shown to be on a 3.7-kb mobile genetic element on the plasmid.
Staphylococcal strains that are resistant to erythromycin, may be susceptible to clindamycin and give a D-shaped inhibition zone around the clindamycin disk with flattening towards erythromycin (an inducible MLSB phenotype). Isolates resistant to both erythromycin and clindamycin with a spherical inhibition zone are known as having a constitutive resistance MLSB (cMLSB) phenotype [7, 8] . Staphylococcal species showing resistance to erythromycin but sensitivity to clindamycin, gave a spherical district of inhibition around clindamycin and was categorized as having an MS (resistant to erythromycin and sensitive to clindamycin) phenotype [8] .
The msrA gene codes for an ATP-dependent transporter that disseminates erythromycin and streptogramin B from the cell environment via energy, and has been recognized only in Staphylococcus species [9] . Also, to date, the mere efflux proteins corresponding for acquiring macrolide resistance described in Staphylococcus species, are ABC transporters encoded by plasmid-borne msr genes [5, 10] . The goal of the current study was phenotypic and genotypic investigation of resistance to MLSB, by a D-test and PCR for gene amplification among MRSA strains obtained from patients admitted to 3 teaching hospitals, in Tehran, Iran.
Material and Methods

Clinical specimens and laboratory identification
In the descriptive cross-sectional study, 106 non-repetitive clinical isolates of MRSA were obtained over 15 
MIC E-test
Vancomycin (VA) MIC E-test strips (ranging from 0.016 to 256 µg/mL and interpretation criteria ≤ 2; S, 4-8; I and ≥ 16; R µg/mL, Liofilchem SRL, Roseto degli Abruzzi, Italy) were used in this study in concordance with the manufacturer's recommendations.
Determination of resistant phenotypes
The resistant phenotypes were identified through the double (Figure 1 ). Of 11 isolates that had the iMLSB resistant phenotype, ermC was positive in 81.8% (n = 9), ermB in 63.6% (n = 7), ermA in 54.5% (n = 6), and ereA in 18.2% (n = 2) of isolates, and out of these, ermA/B/C were co-present in 36.4%
(n = 4). One iMLSB-resistant phenotype (9.1%) carried all of the ermA/B/C and ereA genes ( Table 3) . None of the isolates tested were negative for ereB, msrA and msrB genes. Therefore, 18.2% (n = 2) isolates with iMLSB phenotypes did not have any tested genes.
In isolates with the cMLSB phenotype, the prevalence of ermA, ermB, ermC, msrA, msrB, ereA and ereB were 7 (25.9%), 5 (18.5%), 12 (44.4%), 0 (0.0%), 0 (0.0%), 3 (11.1%) and 0 (0.0%), respectively. Of the 27 cMLSB strains, 6 (22.2%), 4 (14.8%), 1 (3.7%) and 1 (3.7%) were positive for ermA/ermC, ermA/ermB/ ermC, ermA/ermB and ermC/ereA, respectively. In the MS phenotype, ermA, ermB and ermC genes were found in 1 (12.5%), 0 (0.0%) and 3 (37.5%) strains, respectively. Other resistance genes were not found in this phenotype (Figures 2 and 3) .
Discussion
During the last decade, therapeutic drug failure has emerged due to abuse, overuse, and misappropriation of antimicrobial [17] [18] [19] . Infections due to MRSA are significant causes of mortality and morbidity across the world [20] . The highest and lowest frequency of samples were collected in order from the wound and CSF. In addition, the highest antibiotic resistance rate was associated with GM (90.6%), and the lowest was RA (11.3%). All isolates were susceptible to VA and LNZ. Therefore, these antimicrobials are the most effective anti-Staphylococcal agent in our study.
These data are similar to studies performed by Japoni et al [21] , Ghosh et al [11] and Pournajaf et al [22] .
The D-test is easy to perform and interpret, reproducible, and low-cost, but still not commonly used. D-test results of our study demonstrated that 61 (57.5%) isolates were sensitive to both ERY and CC; the frequency of cMLSB, iMLSB, and MS resistance phenotypes were found to be 27 (56.2%), 11 (22.9%), and 8 (16.6%), respectively. These results were similar to studies performed by Aktas et al [23] and Seifi et al [24] , but in contrast to Ghanbari et al [13] , Moosavian et al [25] , Rahbar et al [26] , and Jethwani et al [27] . These conflicts may be related to the prevalence of isolates with inducible resistance that can be dependent on geographic region, arbitrary use of antibiotics by patients, patient's age, species of bacteria, patient group, hospital wards, origin of samples and source of the strains like community or nosocomial. The frequency of inducible rates was also dissimilar from one hospital to another and even among patients [25, 28] . In the current study and in accordance with Mahesh et al [28] , the frequency of the cMLSB resistance phenotype was higher than iMLSB. In contrast, Reddy and Suresh found the frequency of the iMLSB phenotype to be higher than the cMLSB phenotype [29] . The treatment of Staphylococcal infection with resistant strains to iMLSB can lead to the development of cMLSB and failure in CC therapy, therefore detection of resistant strains to iMLSB is more important than detecting other resistant phenotypes.
Since, the occurrence of cMLSB, iMLSB, and MS phenotypes vary in different geographical areas, even among different hospitals, awareness of the regional frequency of MLSB resistant isolates is important for microbiology laboratories to determine whether to perform the D-zone test routinely, or the reporting of all ERY-resistant S. aureus as CC-resistant [29] . As revealed in Table 3 , the most widespread resistance gene was ermC (n = 24/46; 52. 41.1% and ermA; 17.7%) [30] . In concordance with our results, Cetin et al [4] , Schmitz et al [31] , and Westh et al [32] showed that ermA and ermC genes were associated with the majority of resistance to ERY among the MRSA. In contrast to Schmitz et al [31] , the frequency of ermA and ermC genes was 88% and 47%, respectively. These results agree with Aktas et al [23] among the ERY-resistant MRSA collection, as ermC was predominant in strains expressing a cMLSB (n = 12; 44.4%) and iMLSB (n = 9;
81.8%) phenotype.
Out of the 106 isolates in our study, it was interesting that the ereA gene was present in all 5 (10.8%) strains with a resistant phenotype [(cMLSB; 3 (11.1%), iMLSB; 2 (18.2%)].
In contrast with our results, Schmitz et al [31] analyzed 851 clinical isolates of S. aureus, and showed that the ereA gene was not detected. In addition, the ereB gene was only found in an isolate with a cMLSB phenotype (1.0%). We detected no MRSA with msrA and msrB resistance mechanisms. In contrast to our data, resistance to macrolides via efflux (msrA/msrB genes) was only found in MSSA (n = 14/358; 13%) by Schmitz et al [31] , but Lina et al [33] showed the presence of msrA/msrB in both MSSA and MRSA isolates. A notable finding of the present study was that 1 (9.1%) isolate carried all of the ermA/B/C and ereA genes. The prevalence of ermA/C was 13.1% (n = 6) in our isolates. Nikbakht et al [34] showed the simultaneous presence of ermA and ermC in a significant number (n = 39/215, 18.14%) of their isolates. Since strains with inducible resistance may mutate and alter to constitutive resistance, laboratories must correctly identify C susceptibility using the D-zone method for eliminating inducible C resistance. CMLSB was the most frequently encountered phenotypic pattern, with erm (C) being the most prevalent gene, and erm (A, C) the most frequent gene combination. This prevalence is perhaps due to the spread of distinctive clones (which carry ermC and ermA genes) in our area. In agreement with Siberry et al [35] , the proportion of S. aureus with in vitro inducible clindamycin resistance (iCR) may differ by age group, region, and methicillin susceptibility.
We emphasize that clinical laboratories should report in vitro iCR in S. aureus strains and that physicians should be alert of the potential for antimicrobial therapeutic failure when clindamycin is used to treat serious illnesses due to MRSA with in vitro iCR.
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